TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU
| 中文名称 | TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU |
|---|---|
| 中文同义词 | 神经肽 W-23 (人), >95%;神经肽 W-23 (人);化合物NEUROPEPTIDE W-23(HUMAN);神经肽W-23(人类) TFA盐;神经肽W NEURO PEPTIDE W-23 (HUMAN);神经肽W-23(人类)三氟乙酸盐 |
| 英文名称 | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH |
| 英文同义词 | H-TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU-OH;NPW-23 (HUMAN);NEUROPEPTIDE W-23 (HUMAN);TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU;Neuropeptide W-23 (huMan) NPW-23 (huMan);L-Leucine, L-tryptophyl-L-tyrosyl-L-lysyl-L-histidyl-L-valyl-L-alanyl-L-seryl-L-prolyl-L-arginyl-L-tyrosyl-L-histidyl-L-threonyl-L-valylglycyl-L-arginyl-L-alanyl-L-alanylglycyl-L-leucyl-L-leucyl-L-methionylglycyl-;Neuropeptide W-23(human),WYKHVASPRYHTVGRAAGL MGL,NPW-23, >95%;Neuropeptide W23(human),hypetension,anorexigenic effect,Neuropeptide W 23(human),Neuropeptide W-23 (human),NPW 23,GPR7,Inhibitor,Neuropeptide W,GPR8,NPBW1,NPBW2,inhibit,NPW23 |
| CAS号 | 383415-79-0 |
| 分子式 | C119H183N35O28S |
| 分子量 | 2584.01 |
| EINECS号 | |
| 相关类别 | 标准品;Various peptides |
| Mol文件 | 383415-79-0.mol |
| 结构式 |  |
TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU 性质
| 储存条件 | Desiccate at -20°C |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| 水溶解性 | Soluble to 1 mg/ml in sterile water |
NPW-23 increases the I Ca,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7. NPW-23 increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC.
NPW-23 increases pressure-induced vasotone of the rat mesenteric arteries. Importantly, the expression of NPW is decreased in the hypertensive rats. NPW-23 (0.3 nmol, 1.0 nmol, and 3.0 nmol) induces significant increases in mean arterial pressure (MAP) in conscious, freely moving male rats. Rats that receive either 1.0 or 3.0 nmol NPW-23 demonstrate a significant increase in total activity, ambulatory activity, and duration of stereotypy. NPW-23 fails to elevate MAP in rats pretreated with phentolamine. NPW-23-induced increases in total activity, ambulatory activity, and duration of stereotypy are reduced significantly by pretreatment with the orexin type 1 receptor (OX1R) antagonist, SB-408124.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-P1035 | TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU Neuropeptide W-23(human) | 383415-79-0 | 5mg | 4500元 |
| 2024/04/30 | HY-P1035 | Neuropeptide W-23 (human) | 10 mg | 6500元 |